雷莫司琼与格拉司琼预防化疗药物引起的胃肠道反应的临床观察

Preventive effects of ramosetron and granisetron in prevention of gastrointestinal reaction associated with chemotherapeutic agents: a comparative study

目的 观察雷莫司琼预防顺铂或阿霉素所引起的胃肠道反应的疗效及安全性 ,并与格拉司琼进行对比。方法 采用随机自身交叉对照。入选患者随机分为AB组或BA组 ,AB组第 1周期应用雷莫司琼 0 3mg,第 2周期应用格拉司琼 3mg ;BA组则相反。结果 可评价患者 4 7例 ,顺铂组 2 7例 ,阿霉素组 2 0例。化疗后 0～ 2 4h雷莫司琼对食欲不振 ,恶心的控制率优于格拉司琼 (P <0 0 5 ) ;0～ 2 4h雷莫司琼对呕吐的控制率与格拉司琼相似。两组不良反应发生率相似 ,主要为头痛。结论 雷莫司琼是安全、高效的止吐药物 ;与格拉司琼比 ,雷莫司琼更具药效经济学优势。

Objective To compare the efficacy and safety of ramosetron and granisetron in prevention of gastrointestinal reaction induced by cisplatin or adramycin. Methods Fifty chemotherapy-naive patients with histological confirmed malignancies were randomized divided into 2 groups: AB group (ramosetron 0.3mg was given in first cycle and granisetron 3mg in the second cycle) and BA group (these drugs were given in the reverse sequence). The appetite, side effects, such as nausea, vomiting, headache, dizziness, etc. were observed. Results A total of 47 patients, 27 receiving cisplatin and 20 receiving adramycin, were evaluable. 0～24 hours after the treatment, the inhibition rate of anorexia was 72.3% in the ramosetron group, significantly lower than that in the granisetron group (51.1%, P<0.05). The inhibition rate of nausea was 66.0% in the ramosetron group, significantly lower than that in the granisetron group (44.6%, P<0.05), and the inhibition rate of vomiting was 76.6% in the ramosetron group, not significantly different from that in the granisetron group (70.2%). The incidence rate of adverse events was similar in these two groups. The most common adverse event was headache. Conclusion Ramosetron is a safe and effective antiemetic and is more cost-effective than granisetron.